Lexicon Pharmaceuticals, Inc.
LXRX
$0.5339
$0.0020.38%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 31.08M | 5.23M | 3.64M | 2.31M | 1.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.08M | 5.23M | 3.64M | 2.31M | 1.21M |
| Cost of Revenue | 84.00M | 72.90M | 64.61M | 61.35M | 58.97M |
| Gross Profit | -52.92M | -67.67M | -60.97M | -59.04M | -57.77M |
| SG&A Expenses | 131.90M | 142.01M | 134.65M | 125.46M | 112.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 215.90M | 214.91M | 199.26M | 186.81M | 171.52M |
| Operating Income | -184.82M | -209.68M | -195.62M | -184.50M | -170.31M |
| Income Before Tax | -200.40M | -216.39M | -202.11M | -193.58M | -177.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -200.40 | -216.39 | -202.11 | -193.58 | -177.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -200.40M | -216.39M | -202.11M | -193.58M | -177.12M |
| EBIT | -184.82M | -209.68M | -195.62M | -184.50M | -170.31M |
| EBITDA | -184.28M | -209.12M | -195.03M | -183.92M | -169.76M |
| EPS Basic | -0.64 | -0.75 | -0.78 | -0.83 | -0.80 |
| Normalized Basic EPS | -0.38 | -0.47 | -0.48 | -0.51 | -0.49 |
| EPS Diluted | -0.64 | -0.75 | -0.78 | -0.83 | -0.80 |
| Normalized Diluted EPS | -0.38 | -0.47 | -0.48 | -0.51 | -0.49 |
| Average Basic Shares Outstanding | 1.28B | 1.16B | 1.05B | 940.02M | 883.65M |
| Average Diluted Shares Outstanding | 1.28B | 1.16B | 1.05B | 940.02M | 883.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |